Sarah Cannon Research Institute Presents Findings of Blood Cancer Clinical ... MarketWatch (press release) ... excluding Transplantation: (PI3K) Inhibitor, CAL-101 (GS-1101), in Combination with Rituximab Poster I and/or Bendamustine in Patients with Relapsed or Refractory Chronic Saturday, December 10, 5:30-7:30pm PT Lymphocytic Leukemia Co-author: Dr. ... |
